New study tracks safety of biologic drugs in inflammatory bowel disease patients
NCT ID NCT04372108
First seen Nov 01, 2025 · Last updated May 10, 2026 · Updated 25 times
Summary
This observational study looks at the long-term safety of the drug ustekinumab compared to other biologic treatments in adults with Crohn's disease or ulcerative colitis. Researchers will analyze health records from the Department of Defense to track rates of cancer, serious infections, and other risks. About 1,056 participants will be followed to help doctors understand which treatments are safer over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NMCP
RECRUITINGPortsmouth, Virginia, 23708, United States
Conditions
Explore the condition pages connected to this study.